Abstract

Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity, partly due to alterations in lipoprotein quantity, quality and cell cholesterol trafficking. Although cardiovascular disease significantly contributes to mortality excess in RA, cardiovascular prevention has been largely insufficient. Because of limited evidence, optimal strategies for lipid management (LM) in RA have not been determined yet, and recommendations are largely based on expert opinions. In this position paper, we describe abnormalities in lipid metabolism in RA and introduce a new algorithm for estimation of cardiovascular risk (CVR) and LM in RA. The algorithm stratifies patients according to RA-related factors impacting CVR (such as RA activity and severity and medication) and therefore enables a more nuanced approach than other current methods. We propose strategies for monitoring of lipid parameters and treatment of dyslipidemia in RA (including lifestyle, statins and other lipid-modifying therapies, and disease modifying anti-rheumatic drugs). These opinion-based recommendations are meant to facilitate LM in RA until more evidence is available.